molnupiravir

December 31, 2021 | Katabella Roberts

New York State Health Dept. Warns Not Enough Paxlovid or Molnupiravir Antibody Treatment

The New York State Health Department has warned that it does not have enough Paxlovid or Molnupiravir antibody treatment and authorized those of non-white race or Hispanic/Latino ethnicity, as well as individuals with underlying medical conditions that increase their risk for severe illness, to receive the treatment. However, the government body made no mention of whether or not other […]

December 23, 2021 | Jack Phillips

FDA Authorizes Merck’s At-home COVID-19 Pill

The Food and Drug Administration (FDA) on Thursday morning issued an emergency use authorization for Merck’s antiviral pill for COVID-19, more than 12 hours after giving the green light for a similar, oral drug made by Pfizer. Merck’s drug, named molnupiravir, was developed with Ridgeback Biotherapeutics, and it was shown to reduce hospitalizations and deaths from […]

November 30, 2021 | Mimi Nguyen Ly

FDA Advisers Vote to Recommend Merck COVID-19 Pill for Emergency Use Authorization

Outside advisers to the U.S. Food and Drug Administration (FDA) on Tuesday narrowly voted to recommend the agency grant emergency use authorization (EUA) for a drug from Merck and Ridgeback Biotherapeutics to treat COVID-19, called molnupiravir. Members of the FDA’s Antimicrobial Drugs Advisory Committee voted 13 for and 10 against the EUA for molnupiravir, agreeing with […]

November 4, 2021 | Lorenz Duchamps

UK Regulator Approves Merck’s Antiviral COVID-19 Pill in World First

Britain’s medicines regulator has given a green light on Thursday to an antiviral COVID-19 pill jointly developed by U.S.-based Merck and partner Ridgeback Biotherapeutics. The drug, known as molnupiravir, has been recommended by Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) to be used during the early stages of infection, within five days of the onset of symptoms, […]

October 16, 2021 | Zachary Stieber

US Set to Pay $712 Per Patient for Merck’s COVID-19 Pill

Merck is set to get $712 per treatment course for its COVID-19 pill from the U.S. government—even as it costs a fraction of that to produce, and is reportedly on track for a price of $12 in India. The gap between production costs and the price for molnupiravir is gigantic and emblematic of a problem […]

Previous Next